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Abstract
Background: The failure to retain patients or collect primary-outcome data is a common challenge for trials and
reduces the statistical power and potentially introduces bias into the analysis. Identifying strategies to minimise
missing data was the second highest methodological research priority in a Delphi survey of the Directors of UK
Clinical Trial Units (CTUs) and is important to minimise waste in research. Our aim was to assess the current
retention practices within the UK and priorities for future research to evaluate the effectiveness of strategies to
reduce attrition.
Methods: Seventy-five chief investigators of NIHR Health Technology Assessment (HTA)-funded trials starting
between 2009 and 2012 were surveyed to elicit their awareness about causes of missing data within their trial
and recommended practices for improving retention. Forty-seven CTUs registered within the UKCRC network
were surveyed separately to identify approaches and strategies being used to mitigate missing data across trials.
Responses from the current practice surveys were used to inform a subsequent two-round Delphi survey with
registered CTUs. A consensus list of retention research strategies was produced and ranked by priority.
Results: Fifty out of seventy-five (67%) chief investigators and 33/47 (70%) registered CTUs completed the current
practice surveys. Seventy-eight percent of trialists were aware of retention challenges and implemented strategies
at trial design. Patient-initiated withdrawal was the most common cause of missing data. Registered CTUs routinely
used newsletters, timeline of participant visits, and telephone reminders to mitigate missing data. Whilst 36 out of
59 strategies presented had been formally or informally evaluated, some frequently used strategies, such as site
initiation training, have had no research to inform practice.
Thirty-five registered CTUs (74%) participated in the Delphi survey. Research into the effectiveness of site initiation
training, frequency of patient contact during a trial, the use of routinely collected data, the frequency and timing of
reminders, triggered site training and the time needed to complete questionnaires was deemed critical. Research
into the effectiveness of Christmas cards for site staff was not of critical importance.
Conclusion: The surveys of current practices demonstrates that a variety of strategies are being used to mitigate
missing data but with little evidence to support their use. Six retention strategies were deemed critically important
within the Delphi survey and should be a primary focus of future retention research.
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Background
The challenges of recruiting and retaining participants
in clinical trials are well documented [1–4] and address-
ing these is of critical importance. A recent Delphi sur-
vey with directors of UKCRC Clinical Trial Units
(CTUs) established that identifying methods to improve
recruitment was a top methodological research priority
with methods to minimise attrition and the development
of core outcome sets as joint second [5].
These priorities are in line with moves to minimise
waste in research, ensuring that trials are as robust and
cost-effective as possible [6–10]. One of the key ways to
achieve this is to maximise the retention of all recruited
patients in the study and the collection, analysis and
reporting of a complete set of outcomes for them. Whilst
there are a number of projects addressing recruitment
challenges it is important to ensure there is an equal focus
on retention. Recruiting and randomising people who are
not subsequently retained for the measurement of the pri-
mary outcome may be worse for the analysis of the trial
than not randomising that patient at all.
Missing data arises from patients being lost to follow-
up or withdrawing before data collection time points,
difficulties in measuring and recording outcomes for pa-
tients who are retained, incomplete or missing patient-
reported outcomes, or by excluding data from rando-
mised patients from the analysis population. Missing
primary-outcome data in clinical trials is a common
problem which has the potential to reduce the power of
the trial and can introduce bias if the reasons or
amounts of missing data are different across arms. Both
the Food and Drug Administration (FDA) and European
Medicines Agency (EMA) guidelines [11–14] strongly
emphasise the need to mitigate missing data within trial
design and conduct, as statistical methods ‘cannot ro-
bustly recover the estimates from a complete data set’.
Our aim is to understand the current practices
employed by UK trialists to mitigate missing data in
clinical trials. To achieve this we conducted a survey of
chief investigators of National Institute of Health Re-
search (NIHR) Health Technology Assessment (HTA)-
funded trials and CTUs registered within the UK Clin-
ical Research Collaboration (UKCRC) network. A subse-
quent Delphi survey across registered CTUs was
undertaken to establish retention research priorities to
minimise missing data in clinical trials.
Methods
Surveys of current practices for mitigating missing data
Two different surveys of HTA chief investigators and
registered CTUs were used to capture current retention
practices. HTA chief investigators were surveyed to pro-
vide a clinical perspective of retention-based strategies
used within specific trials representing a range of disease
areas. In contrast, registered CTUs were surveyed to
identify non-clinical expertise and insights pertinent
across a wide range of trial designs. Whilst it is possible
some HTA-funded trials engaged the expertise of regis-
tered CTUs, the two surveys were designed to elicit re-
sponses from the different perspectives.
A cohort of 76 NIHR Health Technology Assessment
Programme (HTA)-funded randomised trials were iden-
tified through their website portfolio [15]. The NIHR
HTA portfolio was chosen as it represents the largest
public funder of current and ongoing trials and the start
dates ensured at least 1 year’s recruitment following any
pilot work or delays obtaining governance approvals.
Two-arm, parallel trials were included. Exclusion criteria
were pilot studies, patient preference trials, phase 1 and
2 trials, and studies evaluating longer-term follow-up of
previous trials and substudies. This cohort was identified
as part of a wider project on retention. Parallel trials
with more than two arms were also excluded for
consistency across linked projects.
Chief investigators were surveyed to identify whether
retention concerns were identified or known at the trial
outset and which missing data strategies were imple-
mented either during the trial design or subsequently
during trial conduct (Additional file 1). Survey questions
included the causes of missing data within their current
trials and whether observed levels of missing data were
higher, lower or as expected compared to their estima-
tions at trial outset. Respondents were also asked to rec-
ommend the three most effective retention practices
based on their experience of clinical trials.
A second survey was emailed to 47 registered CTUs
identified from the UK Clinical Research Collaboration
(UKCRC) website in August 2014 (Additional file 2).
Surveys were initially sent to registered CTU directors to
complete or delegate as appropriate. If there was no re-
sponse, attempts were made to identify contact details for
other senior staff such as deputy directors, operational di-
rectors, senior trial managers or senior statisticians. Fifty-
nine strategies to reduce missing data were collated from
the Cochrane review and the published results of previous
surveys [16, 17]. Registered CTUs were asked to identify
which of these strategies they had used within their trials
either during the initial design or later in response to spe-
cific challenges. Registered CTUs also had the opportunity
to suggest strategies that they felt were missing. For each
strategy selected, registered CTUs were asked whether it
was used routinely or occasionally and whether they had
evaluated its effectiveness. Evaluations were classified as
either a formal nested study or an informal evaluation
comparing retention rates before and after implementa-
tion. Questions also explored how frequently sample size
calculations were adjusted for missing data, what percent-
age of missing data was used and the justification for this.
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Both surveys were created in MS Word and distributed
via email to allow collaboration within the relevant trial
teams and registered CTUs.
One author (AK) categorised free-text fields and ana-
lysed binary responses from the surveys using SPSS 22.
Delphi survey
A Delphi survey was used to gain consensus amongst
the registered CTUs to identify which missing data strat-
egies should be prioritised for future research to evaluate
their effectiveness. Registered CTUs were invited to take
part in the Delphi survey due to their knowledge across
clinical trials so that established priorities would be per-
tinent to the majority of trials undertaken.
Forty-seven CTU directors, or their proxy from the
previous survey, were invited by email to take part in a
two-round online Delphi survey. During registration par-
ticipants were given a unique ID number to allow the
survey to be completed across a number of sessions and
link responses between rounds.
A list of 67 missing data strategies were compiled for
use in round 1 based on the results of the surveys shared
with CTUs and HTA chief investigators. Registered
CTU responses directed changes to the 59 strategies ini-
tially used: three strategies were amended for clarity;
four strategies were separated to allow delineation be-
tween strategies aimed at sites and participants; and
similar strategies were grouped together to minimise
Delphi survey burden (Additional file 3: Table S1). Two
topics were removed as they were not used by registered
CTUs (Additional file 3: Table S2). Twelve new strat-
egies were added, 10 of which were influenced by re-
sponses from the chief investigator’s survey. These
predominantly focussed on the timing and frequency
of strategies, e.g. newsletters, patient contact, site con-
tact and questionnaires and were in added in response
to comments in the chief investigator’s survey about
‘regular’ contact.
Participants were invited to score each strategy using a
scale of 1–9 based on the GRADE guidelines [18]. Scores
1–3 indicated that research into the effectiveness of the
retention strategy was not important, 4–6 indicated that it
was important but not critical and 7–9 indicated that re-
search was of critical importance. All survey participants
could suggest additional retention strategies during round
1 and could abstain from scoring any strategy.
All participants who completed round 1 were invited
to participate in round 2 where they were shown a sum-
mary of the group’s scores from the previous round and
given the option of changing their individual scores or
keeping them the same (Fig. 1). All strategies from
round 1 were used in the subsequent round. Additional
strategies suggested by participants were reviewed by
CG and AK for inclusion in round 2.
Incentive prize draws of £75 and £25 high-street gift
vouchers were offered for responses to round 2 within 7
and 12 days, respectively. The aim of the incentive was
to improve response rates and minimise the need for re-
minders. Participants were notified of the incentive
within the email invite to round 2.
Consensus was predefined using criteria used in a
similar methodological priority setting exercise and core
outcome development [5, 19]. Consensus that research
was of critical importance was reached if > 70% of scores
were 7–9 and < 15% of scores were 1–3. Consensus that
research was not important was reached if > 70% of
scores were 1–3 as long as < 15% scores were 7–9. All
research topics from round 2 were ranked according to
the percentage of participants scoring a research topic as
critically important (scores 7–9). Where strategies
achieved the same score they were then ranked order of
the percentage of scores 4–6.
Results
Seventy-six chief investigators were approached to
complete the survey, but one trial responded to confirm
that it did not proceed following the initial pilot and was
excluded from the cohort. Fifty of the remaining 75
(67%) surveys were returned (Fig. 2). A breakdown of re-
sponder role can be found in Additional file 3: Table S3.
Trials represented a broad range of health conditions
and intervention types (Additional file 3: Table S4). Over
Fig. 1 An example of the scoring software used in round 2 of the Delphi survey. Individual participant scores were highlighted in yellow, with
percentage of all respondent scores listed beneath each radio button
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half the trials had closed to recruitment, and 38 (76%)
of the trials were aiming to recruit no more than 1000
participants.
Thirty-nine trials (78%) were aware of retention issues
at the outset of the trial, with 19 (49%) citing challenges
associated with the patient population, such as high
mortality or a mobile population, and 16 (41%) were
concerned about patients not returning data (Additional
file 3: Table S5). Only seven of the 50 trials (14%) stated
that current missing data levels were higher than ex-
pected at trial design.
Forty-one (84%) trials experienced missing data caused
by patient-initiated withdrawal, 30 (61%) through losing
contact with patients and 24 (49%) by patients not
returning data. However, 14 trials (29%) also reported
that data was missing because patients did not attend
visits, 12 (25%) due to clinical staff failing to take mea-
surements and 10 (20%) reported that data was not
provided by clinical staff (Table 1).
Based on the respondent’s experiences of clinical trials,
the most effective practices for mitigating missing data
were robust monitoring and working closely with re-
search sites. Twenty-five (50%) trials recommended
monitoring practices to identify, track and rigorously
follow up missing data, 15 (30%) recommended main-
taining good relationships with trial sites ensuring regu-
lar contact, 11 (22%) highlighted the importance of site
training and 10 (20%) recommended offering multiple
approaches to collect data such as home visits or tele-
phone interviews (Table 2).
Survey of registered CTUs
Thirty-three out of forty-seven (70%) registered CTUs
responded to the survey of current practices. Twenty-
nine (90%) registered CTUs routinely adjust their sample
size to account for missing data of which 19 (66%) used
evidence from other trials to inform the levels of ad-
justment, nine (31%) used their own past experience,
four (14%) used pilot data, two (7%) used estimated
figures from the chief investigator, two (7%) used a
standard 20% dropout rate and one (3%) used a best
guess (Additional file 3: Table S9).
Table 1 Current causes of missing data within the cohort of Health Technology Assessment Programme (HTA)-funded trials
Causes of missing data Number of trials (%)
n = 49a
Patients withdrawing 41 (84%)
Losing contact with patients 30 (61%)
Patients not returning questionnaire 24 (49%)
Patient deaths 23 (47%)
Clinicians withdrawing patients 17 (35%)
Patients not attending a visit/clinic 14 (29%)
Missed measurement by clinical staff 12 (25%)
Patient outcomes other than death preventing measurement, e.g. coma, too ill to complete measures 10 (20%)
Data not provided by clinical staff 10 (20%)
Other 6 (12%)
Technology problems 4 (8%)
Laboratory problems 2 (4%)
Survey respondents chose all causes of missing data observed in their trial.aOne person did not complete the question
Fig. 2 Cohort of National Institute of Health Research (NIHR) Health
Technology Assessment Programme (HTA)-funded trials. A search of
the NIHR HTA portfolio website was conducted on 23 September
2014 using a keyword ‘randomised’, limited to primary research
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Newsletters were the most routinely used missing data
strategy reported by 23 registered CTUs (70%) (Table 3).
A total of 30 registered CTUs reported using newsletters
at some point to mitigate missing data, 20 of which used
them to communicate with sites, one used them to com-
municate with patients and nine registered CTUs used
them with both audiences.
Nineteen registered CTUs (58%) reported routinely
using a timeline of participant visits and the inclusion of
a prepaid envelope for questionnaires, 18 (55%) regularly
used telephone reminders, data collection scheduled
with routine care and site initiation training on missing
data. Seventeen (52%) of registered CTUs reported
occasionally using routinely collected data, 15 (45%)
occasionally used follow-up through patient notes, 14
(42%) contacting GPs for missing data/to trace pa-
tients, 13 (39%) patient diaries, SMS (text) reminders
and re-imbursement of participant expenses. No-one
reported using a crèche service, behavioural motiv-
ation, charity donations or public draws such as na-
tional lottery tickets.
Thirty-one planned, ongoing or complete nested ran-
domised control trials evaluations were reported for 26
out of the 59 (44%) different missing data strategies.
Thirty-five informal evaluations of 23 interventions
assessed effectiveness by comparing retention before
and after the implementation of a retention strategy. In
total, 36 of the 59 listed strategies had had some form
of evaluation (Table 3). However, no assessments of site
initiation training or a timeline of participant visits had
been undertaken despite their frequent use by regis-
tered CTUs.
Delphi survey
Thirty-five (74%) registered CTUs responded to round 1
of the Delphi survey with 34 (97%) completing round 2.
Two people independently responded on behalf of one
registered CTU. Both sets of answers were included and
we report the analysis for 36 responses in round 1 and
35 responses in round 2.
In round 1 consensus was reached on two strategies;
the use of routinely collected data (72%) and site initi-
ation training on missing data (75%) (Table 4).
Participants suggested four new strategies during
round 1 which were included in round 2: research
nurse teleconferences; the use of patient-reported out-
come measures (PROMs) versus clinician-collected out-
comes; format of newsletters and mode of delivery;
availability of blinded outcome assessors to ensure data
availability and quality.
Nineteen (54%) of those completing round 2 of the
survey responded by the first prize draw deadline, a fur-
ther nine (26%) by the second prize draw deadline and
three (9%) completed the survey after the incentives
ended but before the survey closed. A further four
(11%) completed the survey after it had officially closed
following email or telephone communication but were
also included.
In round 2 consensus was reached for seven interven-
tions (Table 4). Consensus criteria for critically import-
ant research were met for: site initiation training on
missing data; frequency of patient contact during the
trial; use of routinely collected data; frequency and tim-
ing of reminders; triggered site training on missing data
and the length of time needed to complete question-
naires. Research into Christmas and birthday cards for
site staff was found to be of low importance by over
70% of respondents.
Discussion
Surveys of current practices and a Delphi survey have
highlighted routinely used approaches within the UK,
the lack of evidence informing practice and future meth-
odological research priorities within retention.
A strong focus has been placed on improving recruit-
ment in clinical trials and this is routinely monitored
and accepted as a key performance indicator of sites
impacting funding received [20]. However, attention
needs to be extended to cover the retention of rando-
mised participants with sites monitored and rewarded
accordingly. Whilst HTA chief investigators are aware
of retention issues and registered CTUs are regularly
revising sample sizes and proactively implementing a
broad range of strategies to maintain contact with pa-
tients, improve questionnaire and data return, minimise
patient burden and incentivise patients, retention is
Table 2 Top five recommended practices to mitigate missing data recommended by chief investigators
Retention strategy Number of respondents (%)
n = 50
Monitoring (procedures, methods and systems for monitoring data return and following up outstanding data) 25 (50%)
Good site relationship/regular contact with sites to ensure buy in 15 (30%)
Site training (initiation training and triggered training) 11 (22%)
Multiple methods of data collection 10 (20%)
Well-chosen measures and outcomes 6 (12%)
See Additional file 3: Table S7 for complete list of recommend practices
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Table 3 Missing data interventions and reported evaluations into their effectiveness (registered Clinical Trial Unit (CTU) survey
Questions 6 and 7)
Missing data intervention Respondents who
have used the
intervention
(% of all survey
respondents, n = 33)
Used routinely
(% of all survey
respondents,
n = 33)
Used
occasionally
(% of all survey
respondents,
n = 33)
No response for
frequency of use
(% of respondents
who used
intervention)
Before/
after
evaluation
(informal)
Nested
RCT
evaluation
(formal)
Total
evaluations
Newslettersa 30 (91%) 23 (70%) 5 (15%) 2 (7%) 2 2 4
A timeline of participant visits for sites 24 (73%) 19 (58%) 4 (12%) 1 (4%) 0 0 0
Inclusion of prepaid envelope
(questionnaires)b
28 (85%)c 19 (58%) 6 (18%) 1 (4%) 0 1 1
Telephone reminders 28 (85%) 18 (55%) 9 (27%) 1 (4%) 2 1 3
Data collection scheduled with
routine care
25 (76%) 18 (55%) 6 (18%) 1 (4%) 1 1 2
Site initiation training on missing data 19 (58%) 18 (55%) 0 (0%) 1 (5%) 0 0 0
Investigator meetings face to face 22 (67%) 17 (52%) 5 (15%) 0 (0%) 0 1 1
Routines site visits by CTU staff 23 (70%) 15 (45%) 8 (24%) 0 (0%) 1 0 1
Targeted recruitment of sites/GPs 21 (64%) 15 (45%) 6 (18%) 0 (0%) 0 2 2
Flexibility in appointment times 21 (64%) 15 (45%) 4 (12%) 2 (10%) 1 1 2
Communication of trial results 20 (61%) 15 (45%) 3 (9%) 2 (10%) 1 0 1
Investigator teleconferences 22 (67%)d 15 (45%) 8 (24%) 0 (0%) 0 1 1
Questionnaires completed in clinicb 22 (67%) 15 (45%) 5 (15%) 2 (9%) 1 1 2
Minimising frequency of questionnairesb 21 (64%) 15 (45%) 3 (9%) 3 (14%) 0 0 0
Short questionnaireb 24 (73%) 14 (42%) 9 (27%) 1 (4%) 0 1 1
Collecting multiple contact details 22 (67%) 13 (39%) 8 (24%) 1 (5%) 2 1 3
Email reminders 21 (64%) 13 (39%) 6 (18%) 2 (10%) 4 0 4
Postal reminders 23 (70%) 12 (36%) 10 (30%) 1 (4%) 2 2 4
Total design method for Questionnairesb 15 (46%) 12 (36%) 3 (9%) 0 (0%) 1 1 2
Re-imbursement of participant expenses 24 (73%)e 11 (33%) 12 (36%) 0 (0%) 1 1 2
Triggered site training on missing data 23 (70%) 11 (33%) 12 (36%) 0 (0%) 0 0 0
Use of routinely collected data 29 (88%) 10 (30%) 17 (52%) 2 (7%) 2 1 3
Contact GPs for missing data/trace
patients
27 (82%) 10 (30%) 14 (42%) 3 (11%) 0 1 1
Patient diaries 26 (79%) 10 (30%) 13 (39%) 3 (12%) 1 0 1
Enhanced cover letter (questionnaires)b 14 (43%) 9 (27%) 5 (15%) 0 (0%) 1 2 3
Staggered per patient payments to sites 20 (61%) 8 (24%) 12 (36% 0 (0%) 0 0 0
Patient data entry 18 (55%) 8 (24%) 8 (24%) 2 (11%) 0 1 1
Trial identity cards 14 (43%) 8 (24%) 5 (15%) 1 (7%) 0 0 0
Telephone questionnaires 20 (61%) 7 (21%) 11 (33%) 2 (10%) 2 1 3
Trial website 18 (55%) 7 (21%) 10 (30%) 1 (6%) 0 0 0
Taking contact details for a friend/family 13 (40%) 7 (21%) 6 (18%) 0 (0%) 0 1 1
Long but clear questionnaireb 10 (31%) 7 (21%) 2 (6%) 1 (10%) 0 0 0
Only collecting the primary outcome for
patients with missing data
17 (52%) 6 (18%) 10 (30%) 1 (6%) 2 1 3
Gift 18 (55%) 6 (18%) 10 (30%) 2 (11%) 1 1 2
ONS flagging 16 (49%)e 6 (18%) 7 (21%) 2 (13%) 0 0 0
Flexibility in appointment locations 14 (43%) 6 (18%) 6 (18%) 2(14%) 1 0 1
Money/gift voucher given on
completion of a milestone
17 (52%) 5 (15%) 12 (36%) 0 (0%) 1 0 1
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currently not used as a key performance indicator
within UK research networks and is seldom linked to
per-patient payments for research costs.
Whilst survey formats differed, the perspectives of
chief investigators and registered CTUs were similar.
Chief investigator’s recommendation of good monitoring
processes to identify and address any problems with data
collection was congruent with registered CTUs’ routine
use of strategies that might facilitate this such as tele-
phone reminders and routine site visits. Both registered
CTUs and chief investigators also placed a strong em-
phasis on training and working with local research site
staff to minimise missing data, with six of the top 10
strategies routinely used by registered CTUs focussed
in this area.
However, many strategies continue to lack evidence
for their effectiveness. Whilst 61% (36/59) of strategies
had some evaluation reported by registered CTUs, exist-
ing evidence was typically low level: 21 strategies had
only one nested RCT, and only five strategies had two
evaluations that could be combined in a meta-analysis
assuming that there was sufficient homogeneity. It is im-
portant to replicate findings in multiple trials to ensure
the applicability and generalisability and because results
of nested RCTs may be more convincing if they span
multiple trials.
Table 3 Missing data interventions and reported evaluations into their effectiveness (registered Clinical Trial Unit (CTU) survey
Questions 6 and 7) (Continued)
Contacting patients between visits 13 (40%) 4 (12%) 9 (27%) 0 (0%) 0 0 0
Christmas and birthday cards 13 (40%) 4 (12%) 9 (27%) 0 (0%) 0 1 1
Freephone number for updating contact 7 (22%) 4 (12%) 3 (9%) 0 (0%) 0 0 0
Follow-up through patient notes only 19 (58%)e 3 (9%) 15 (45%) 0 (0%) 0 0 0
Transport to and from appointments 8 (25%) 3 (9%) 4 (12%) 1 (13%) 0 0 0
SMS text reminders 16 (49%)e 2 (6%) 13 (39%) 0 (0%) 3 1 4
Trial certificate 8 (25%) 2 (6%) 6 (18%) 0 (0%) 0 0 0
Medical questions first in questionnaireb 2 (7%) 2 (6%) 0 (0%) 0 (0%) 0 0 0
Generic questions first in questionnaireb 3 (10%) 2 (6%) 0 (0%) 1 (33%) 0 0 0
Questionnaires sent less than 3 weeks
after a visitb
2 (7%) 2 (6%) 0 (0%) 0 (0%) 0 0 0
Other (questionnaires) b 2 (7%) 2 (6%) 0 (0%) 0 (0%) 0 0 0
Money/gift voucher given regardless 8 (25%) 1 (3%) 7 (21%) 0 (0%) 1 2 3
Case management 3 (10%) 1 (3%) 2 (6%) 0 (0%) 0 0 0
Other 2 (7%) 1 (3%) 1 (3%) 0 (0%) 0 0 0
Personal touch (questionnaires)b 9 (28%) 1 (3%) 8 (24%) 0 (0%) 0 0 0
Questions about health issue first in
questionnaireb
1 (4%) 1 (3%) 0 (0%) 0 (0%) 1 0 1
Questionnaires sent before clinic visitb 5 (16%) 1 (3%) 4 (12%) 0 (0%) 0 1 1
Prize draw limited to trial participants 6 (19%) 0 (0%) 6 (18%) 0 (0%) 0 0 0
Social media 5 (16%)e 0 (0%) 3 (9%) 1 (20%) 0 0 0
Priority or recorded post (questionnaires)b 4 (13%) 0 (0%) 3 (9%) 1 (25%) 0 0 0
Crèche service 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 0 0
Behavioural motivation 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 0 0
Charity donation 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 0 0
National lottery ticket or similar
public draw
0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 0 0
Total 35 31 66
Number of strategies that have been evaluated (% of all strategies, n = 59) 23 (39%) 26 (44%) 36 (61%)
aOne case where the newsletters were used with patients only, nine cases where newsletters were used with both patients and research sites, and 20 cases where
they were only used with research sites. bStrategies used to enhance questionnaire response rates from Question 7 of the registered CTU survey cTwo respondent
stated that they would not use this intervention again. dOne person reported both occasional and routine use. eOne respondent stated that they would not use
this intervention again
CTU Clinical Trial Unit, GP general practitioner, ONS Office for National Statistics, RCT randomised controlled trial, SMS short message service
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Table 4 Delphi survey research priorities for assessing the effectiveness of missing data interventions
Scores Round 1 Round 2 Ranking
Missing data intervention %1–3 %4–6 %7–9 %1–3 %4–6 %7–9
Site initiation training on missing dataa 6% 19% 75% 6% 11% 83% 1
Frequency of patient contact during the triala 3% 31% 66% 0% 21% 79% 2
Use of routinely collected dataa 6% 22% 72% 6% 17% 77% 3
Frequency and timing of remindersa 0% 34% 66% 0% 24% 76% 4
Triggered site training on missing dataa 6% 31% 64% 3% 23% 74% 5
Length/time needed to complete the questionnairea 11% 28% 61% 9% 17% 74% 6
Frequency of contact between central trial staff and investigators 11% 31% 58% 6% 26% 69% 7
Impact of site recruitment rates on data collection 9% 31% 60% 9% 23% 69% 8
Postal or online questionnaires 3% 39% 58% 3% 31% 66% 9
Frequency of questionnaires 6% 36% 58% 6% 29% 66% 10
Data collection scheduled with routine care 8% 31% 61% 9% 26% 66% 11
ONS flagging of patients 15% 27% 58% 16% 19% 66% 12
Impact of local site researcher/clinical staff continuity 6% 34% 60% 3% 32% 65% 13
Telephone reminders 9% 34% 57% 9% 26% 65% 14
Contacting GPs for missing data or to trace patients 17% 31% 51% 9% 26% 65% 14
Only collecting the primary outcome for patients with missing primary and secondary data 6% 32% 62% 6% 30% 64% 16
Email reminders 0% 45% 55% 3% 34% 63% 17
Patient data entry, e.g. use of mobile phone applications (apps), online data or other systems 9% 34% 57% 6% 32% 62% 18
Staggered per patient payments based on patient progress and data collection 9% 29% 63% 9% 29% 62% 19
A timeline reminder of participant visits for sites 11% 37% 51% 9% 32% 59% 20
Flexibility in appointment times, e.g. data collection window 6% 42% 53% 6% 37% 57% 21
Site selection strategies 11% 37% 51% 11% 31% 57% 22
Questionnaires completed in the presence of researchers/clinical staff 11% 39% 50% 11% 31% 57% 22
Case management, e.g. arranging appointments and helping patients access health care 19% 35% 45% 20% 23% 57% 24
Re-imbursement of participant expenses 11% 37% 51% 6% 38% 56% 25
Postal reminders 11% 40% 49% 9% 35% 56% 26
Questionnaires returned to local sites vs central office, e.g. is monitoring of response rates
and follow-up of missing questionnaires best performed by local sites or central trial offices
9% 37% 54% 9% 35% 56% 26
Data collected by phoning the patient 11% 37% 51% 9% 37% 54% 28
Inclusion of prepaid envelope 22% 36% 42% 23% 26% 51% 29
SMS text reminders 12% 45% 42% 13% 38% 50% 30
Teleconference meetings with investigators 11% 42% 47% 9% 43% 49% 31
Clinician/researcher-collected outcomes versus PROMS (patient-reported outcome measures) NA NA NA 13% 41% 47% 32
Location where questionnaires are completed, e.g. home or clinic 8% 42% 50% 9% 46% 46% 33
Retention and withdrawal information within the Patient Information Sheets 14% 42% 44% 14% 40% 46% 34
Follow-up through patient notes only 14% 43% 43% 9% 47% 44% 35
Research nurse teleconferences or face-to-face meetings NA NA NA 3% 54% 43% 36
Use of social media to contact participants 13% 47% 41% 10% 48% 42% 37
Flexibility in appointment locations, e.g. home or clinic 14% 39% 47% 14% 46% 40% 38
Site newsletters 11% 44% 44% 14% 49% 37% 39
Availability of blinded outcome assessors to ensure data availability and quality NA NA NA 29% 35% 35% 40
Routine site visits by CTU staff 8% 53% 39% 3% 63% 34% 41
Timing of sending questionnaires, e.g. before or shortly after a visit 11% 51% 37% 9% 57% 34% 42
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Many of the research strategies prioritised within the
Delphi survey relate to methods routinely used by reg-
istered CTUs. Methods all have implications for re-
source use and despite their frequent use in current
practice there was an absence of evidence to support
them. Their prioritisation within the Delphi survey
likely reflects the desire of registered CTUs to have
their practices supported by evidence to ensure that
they direct their limited resources to effective methods.
More embedded trials (SWATs: Studies Within A Trial)
[21] are needed to further the evidence base and avoid
wasting resources on unproven and potentially ineffective
retention strategies. The MRC-funded START [22] project
focusses on SWATs targeting improved recruitment
and a similar initiative could be beneficial to improve
the evidence base for retention. The results of the
Delphi survey provide a list of priorities for future
SWATs.
Site initiation training was routinely used within regis-
tered CTUs and a top practice recommended by chief
investigators, but was one of the strategies with no re-
ported evaluations. It is, therefore, unsurprising that
this strategy was identified as the top priority for future
methodological research during the Delphi survey.
Triggered site training also reached consensus criteria
in round 2 reiterating the need to examine how multi-
centre trials address attrition when patient contact and
outcome measurement are often delegated to sites.
Table 4 Delphi survey research priorities for assessing the effectiveness of missing data interventions (Continued)
Collecting multiple contact details for participants 24% 38% 38% 24% 42% 33% 43
Face-to-face meetings with investigators 6% 58% 36% 6% 63% 31% 44
Patient diaries to collect data 11% 50% 39% 14% 54% 31% 45
Total Design Method (Dillman [31]), a specific approach to maximise questionnaire response
rates that utilises cover letters, reminders and resending questionnaires
16% 44% 41% 16% 53% 31% 46
Behavioural motivation strategies, e.g. workshop for patients to help facilitate completion
of intervention and follow-up
24% 45% 30% 30% 42% 27% 47
Format of newsletters and mode of delivery NA NA NA 12% 62% 26% 48
Offer of trial results for participants 11% 58% 31% 11% 63% 26% 49
Frequency of newsletters 8% 64% 28% 6% 74% 20% 50
Question order, e.g. health-related, generic or medical questions first 11% 61% 28% 6% 74% 20% 50
Patient newsletters 16% 59% 25% 13% 68% 19% 52
Open trial design 41% 44% 15% 42% 45% 13% 53
Timing of monetary/gift voucher for participants, e.g. given conditionally on completion
of assessment or unconditionally at the beginning or end of trial
29% 47% 24% 27% 61% 12% 54
Monetary incentives or gift voucher incentives for participants 29% 44% 26% 30% 58% 12% 55
Transport to and from appointments 14% 63% 23% 15% 76% 9% 56
Taking contact details for friends/family of participants 31% 50% 19% 32% 61% 6% 57
Gift for participant 42% 45% 13% 42% 52% 6% 58
Prize draw limited to trial participants 41% 44% 16% 34% 59% 6% 59
Enhanced cover letter 24% 55% 21% 21% 73% 6% 60
Trial certificate 44% 50% 6% 50% 44% 6% 61
Trial website 31% 53% 17% 26% 69% 6% 62
The use of a Freephone number for updating participant’s contact details 35% 58% 6% 40% 57% 3% 63
Trial identity cards 39% 52% 10% 42% 55% 3% 64
Use of social media to contact site staff 33% 55% 12% 38% 59% 3% 65
Gift for site staff 45% 52% 3% 36% 61% 3% 66
Christmas and/or birthday cards for participants 48% 45% 6% 64% 33% 3% 67
Type of post used, e.g. priority, standard or recorded post 34% 54% 11% 29% 68% 3% 68
Personal touch, e.g. handwritten letter or addition of post it notes 26% 71% 3% 27% 73% 0% 69
Offer of a crèche service 50% 46% 4% 57% 43% 0% 70
Christmas cards for site staffb 67% 33% 0% 82% 18% 0% 71
aConsensus was achieved that the future research was of critical importance. bConsensus was achieved that future research was not important
CTU Clinical Trial Unit, GP general practitioner, NA not applicable, ONS Office for National Statistics, SMS short message service
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Research into site training is supported by the results
of recent workshops reviewing recruitment and reten-
tion strategies [16, 23]. Anecdotal evidence suggests that
coordinated approaches with local sites and strong clin-
ical buy-in can help to retain patient populations per-
ceived to be at risk of attrition [23]. However, analysis of
the methods and content of site training have largely
focussed on the impact on informed consent and re-
cruitment [24–28], rather than retention of patients and
collection of outcome data where there is a paucity of
academic literature. Lienard conducted a nested RCT in-
vestigating the effect of training and subsequent moni-
toring visits on data return and quality but found no
difference because the study was terminated early [29].
As the Delphi survey topic titles were broad, further
work is needed to explore how site training might im-
pact on retention. Chief investigators commented on
both content and methods for delivering training within
their survey responses. They described using training to
communicate data collection priorities and processes, in-
cluding the opportunity to develop bespoke processes
for individual sites. Suggestions of training methods in-
cluded interactive presentations, newsletters and re-
fresher training. Existing trial processes (e.g. routine use
of newsletters, regular contact with sites) may be able to
support such site training as well as enhancing or main-
taining the buy-in of research site staff. Berger supports
this, communicating how training was important in
maintaining the continuity of research staff and equip-
ping them to monitor and address withdrawal reasons,
negotiate complaints and reiterate the importance of
data collection with patients to improve retention [30].
The choice of outcomes for future SWATs are an im-
portant consideration for future research. A Cochrane
review identified 38 nested randomised studies of re-
tention interventions of which 34 aimed to improve
questionnaire return [17]. In our survey of chief investi-
gators, patient withdrawal was the most widely reported
cause of missing data and yet there is little published
evidence for effective strategies. The four studies meas-
uring patient retention assessed behavioural motivation,
case management and a factorial design of a trial cer-
tificate and gift. No effect was found and our research
shows that these strategies are, at best, infrequently
used by registered CTUs.
Future research
The ranked list of research priorities from the Delphi
survey provides a ‘roadmap’ to address uncertainties and
systematically evaluate key strategies. Six topics were
deemed critically important and should be a primary
focus of future retention research.
We strongly recommend that future studies take
account of the range of causes of missing data
reported by chief investigators and previous studies.
Retention strategies applicable to a range of trial de-
signs, such as site training, frequency of patient con-
tact and the frequency and timing of reminders,
should assess impact on patient withdrawal, patients
lost to follow-up and clinical staff failing to record
primary-outcome measurements as well as question-
naire response rates.
Many Delphi survey participants commented on the
challenges of scoring the importance of retention strat-
egies when these are often chosen to address challenges
within specific trial designs or populations. Considering
the number of strategies discussed it was not feasible to
explore this and participants were encouraged to score
strategies based on the trials frequently delivered within
their CTU. Consequently, the results reflect a ranked list
of priorities that will have the broadest impact across
the range of trials currently undertaken in the UK. Fu-
ture research is needed to explore the effectiveness of
different strategies for specific trial designs, settings and
patient populations.
Strengths and limitations
To our knowledge this is the first study to develop a re-
search agenda for evaluating the effectiveness of reten-
tion strategies and so provides a valuable reference point
for future methodological work.
A systematic review and surveys of registered CTUs
and HTA chief investigators were used to compile the
initial list of retention strategies for the Delphi survey.
The two different surveys sought to capture both the
practical experience of chief investigators within spe-
cific trials and the broader experience of registered
CTUs that work across multiple trials and different trial
designs. Registered CTUs were invited to complete the
Delphi survey in order to create a priority list that was
applicable to the broad range of trials represented
within the UK.
Whilst the study was researcher-led and did not in-
clude public or patient perspectives, all three surveys
benefited from strong response rates and the Delphi
survey retained the majority of participants. Only one
person failed to complete round 2 suggesting that the
results are unlikely to be affected by attrition bias. The
high response rate is attributed to engaging an active
network of registered CTUs that were invested in the
topic having previously agreed that it was of critical
importance [5].
Analysis of the number of retention strategies evalu-
ated by registered CTUs should be considered with
some caution as missing responses could not be iden-
tified. However, this information did not influence the
Delphi process or the ranking of retention strategies
for future evaluation.
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Conclusion
Whilst trials are proactively implementing a range of
strategies to address retention challenges, further evi-
dence is needed to inform practice and minimise
waste on ineffective methods.
The Delphi survey results provide methodological re-
searchers and trialists with a research agenda and a
means of effectively channelling resources towards the
assessment of retention strategies that impact UK trials.
Research should focus on site training, frequency of pa-
tient contact, the use of routinely collected data, the fre-
quency and timing of reminders and the length of time
needed to complete questionnaires. Research outcomes
should reflect the wide range of missing data causes and,
in particular, should include an assessment of their im-
pact on patient withdrawal which was reported to be the
most common cause of missing data.
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